451 related articles for article (PubMed ID: 28681133)
1. Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
Shah SJ
J Cardiovasc Transl Res; 2017 Jun; 10(3):322-336. PubMed ID: 28681133
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.
Shah SJ
J Cardiovasc Transl Res; 2017 Jun; 10(3):233-244. PubMed ID: 28585183
[TBL] [Abstract][Full Text] [Related]
3. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
Luo H; Zhang C; Wang J; Zhu J; Jia X
Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
[TBL] [Abstract][Full Text] [Related]
4. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.
Polsinelli VB; Shah SJ
Expert Opin Pharmacother; 2017 Mar; 18(4):399-409. PubMed ID: 28129699
[TBL] [Abstract][Full Text] [Related]
5. [Heart failure with preserved ejection fraction: an update on diagnosis and treatment].
Gori M; D'Elia E; Zambelli G; Senni M
G Ital Cardiol (Rome); 2020 Feb; 21(2):119-127. PubMed ID: 32051635
[TBL] [Abstract][Full Text] [Related]
6. Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
Luo Y; Ahmad FS; Shah SJ
J Cardiovasc Transl Res; 2017 Jun; 10(3):305-312. PubMed ID: 28116551
[TBL] [Abstract][Full Text] [Related]
7. Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.
Xanthopoulos A; Triposkiadis F; Starling RC
Trends Cardiovasc Med; 2018 Aug; 28(6):392-400. PubMed ID: 29471985
[TBL] [Abstract][Full Text] [Related]
8. Noncardiac comorbidities in heart failure with preserved ejection fraction - commonly ignored fact.
Liu M; Fang F; Yu CM
Circ J; 2015; 79(5):954-9. PubMed ID: 25739578
[TBL] [Abstract][Full Text] [Related]
9. Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and Therapeutic Implications.
Galli E; Bourg C; Kosmala W; Oger E; Donal E
Heart Fail Clin; 2021 Jul; 17(3):499-518. PubMed ID: 34051979
[TBL] [Abstract][Full Text] [Related]
10. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Fukuta H; Goto T; Wakami K; Ohte N
Eur J Prev Cardiol; 2016 Jan; 23(1):78-85. PubMed ID: 25520380
[TBL] [Abstract][Full Text] [Related]
11. How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.
Shah SJ; Cogswell R; Ryan JJ; Sharma K
Curr Cardiol Rep; 2016 Dec; 18(12):122. PubMed ID: 27796858
[TBL] [Abstract][Full Text] [Related]
12. INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.
Reddy YNV; Lewis GD; Shah SJ; LeWinter M; Semigran M; Davila-Roman VG; Anstrom K; Hernandez A; Braunwald E; Redfield MM; Borlaug BA
Circ Heart Fail; 2017 May; 10(5):. PubMed ID: 28476756
[TBL] [Abstract][Full Text] [Related]
13. 20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.
Shah SJ
J Am Soc Echocardiogr; 2019 Nov; 32(11):1379-1395.e2. PubMed ID: 31679580
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review.
Vaduganathan M; Michel A; Hall K; Mulligan C; Nodari S; Shah SJ; Senni M; Triggiani M; Butler J; Gheorghiade M
Eur J Heart Fail; 2016 Jan; 18(1):54-65. PubMed ID: 26634799
[TBL] [Abstract][Full Text] [Related]
15. The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies.
Fukuta H; Goto T; Wakami K; Ohte N
Int J Cardiol; 2017 Feb; 228():4-10. PubMed ID: 27863360
[TBL] [Abstract][Full Text] [Related]
16. Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project.
Donal E; Lund L; Linde C; Daubert JC;
Arch Cardiovasc Dis; 2010; 103(6-7):404-10. PubMed ID: 20800804
[TBL] [Abstract][Full Text] [Related]
17. Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials.
Jonnalagadda SR; Adupa AK; Garg RP; Corona-Cox J; Shah SJ
J Cardiovasc Transl Res; 2017 Jun; 10(3):313-321. PubMed ID: 28585184
[TBL] [Abstract][Full Text] [Related]
18. Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction.
Ahmad FS; Luo Y; Wehbe RM; Thomas JD; Shah SJ
Heart Fail Clin; 2022 Apr; 18(2):287-300. PubMed ID: 35341541
[TBL] [Abstract][Full Text] [Related]
19. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
20. Heart failure with preserved ejection fraction: an ongoing enigma.
Rose-Jones LJ; Rommel JJ; Chang PP
Cardiol Clin; 2014 Feb; 32(1):151-61, ix-x. PubMed ID: 24286586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
